Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
pp. 4316 - 4327

Naloxone-An Overview of Opioids Antidote

[1]- Adel Mater Aldhafeeri,[2]- Aziz Saleh Suleman Albalwi ,[3]-Salah Mohammed Mohammed Alsheredi ,[4]-Ali Lnad Hamod Alanazi,[5]-Muhammed Abdulkareem Alhazoom ,[6]- Saeed Ali Yahya Najmi .,[7]-Saad Saud Saad Alrashoud ,[8]-Ibrahim Mohammed Alfoud,[9]-Attia Mahdi Ibrahim Bouity,[10]-Khalid Jazi Aloatibi,[11]-Abdullrahman Molfi Aldhafeeri,[12]- Wedad Salem Alanazi ,[13]-Abdulrahman Mutiq Alharbi,[14]-Ola Jameel Filfilan,[15]-Saeed Mohameed Gaman Alzahrani

[1] Ksa, Ministry Of Health, Hafer Albaten Health Cluster
[2] Ksa, Ministry Of Health, Eradah & Mental Health Complex-Eradah Services3-
[3] Ksa, Ministry Of Health, King Faisal General Hospital
[4] Ksa, Ministry Of Health, Hafar Albatrn Health Cluster
[5] Ksa, Ministry Of Health, King Faisal Hospital
[6] Ksa, Ministry Of Health, Samtah General Hospital
[7] Ksa, Ministry Of Health, Riyadh First Health Cluster , General Alaflaj Hospital
[8] Ksa, Ministry Of Health, Tabuk Health Cluster
[9] Ksa, Ministry Of Health, King Fahad Central Hospital
[10]Ksa, Ministry Of Health, Ruwaydah Alard General Hospital
[11]Ksa, Ministry Of Health, Long Care Hospital. Hafer Albaten
[12]Ksa, Ministry Of Health, Madinah Manwwerah
[13]Ksa, Ministry Of Health, King Salman Bin Abdulaziz Medical City
[14]Ksa, Ministry Of Health, Compliance Department, Makkah Region
[15]Ksa, Ministry Of Health, Executive Management Of Inventory Control

Abstract:

Background: Opioid overdose rates have surged in the United States, especially in rural areas, where opioid use disorder (OUD) has significantly increased morbidity and mortality. The opioid crisis is fueled by several factors, including the prevalence of synthetic opioids like fentanyl. Naloxone, a medication used for over five decades, has become a vital tool in reversing opioid toxicity, particularly in emergency settings.

Aim: This review aims to provide an overview of naloxone, its pharmacology, mechanisms, clinical applications, and its critical role in mitigating opioid overdose deaths.

Methods: This article synthesizes current knowledge on naloxone, focusing on its indications, effectiveness, administration methods, and available dosage forms. Data was drawn from medical guidelines, research studies, and CDC reports.

Results: Naloxone has demonstrated significant efficacy in reversing the effects of opioid overdoses, particularly respiratory depression. It is now widely available, including as an over-the-counter option in 43 states. Various administration routes such as intravenous, intranasal, and intramuscular provide flexibility for use in diverse clinical and prehospital environments. Off-label uses for naloxone, such as managing opioid use disorder and pruritus in cancer patients, have shown promise, though further research is necessary.

Conclusion: Naloxone remains an essential component of the public health response to the opioid crisis. Its widespread availability and diverse administration methods have enabled timely intervention in opioid overdose emergencies, saving countless lives. Increased awareness and access are necessary to reduce opioid overdose fatalities, particularly in rural communities heavily impacted by the crisis.

Key words: Naloxone, opioid overdose, opioid use disorder, opioid toxicity, overdose reversal, respiratory depression, public health, fentanyl.

Received: 05 october 2023 **Revised:** 19 November 2023 **Accepted:** 02 December 2023

Introduction:

Over the past two decades, there has been a substantial rise in opioid overdose rates across the United States, with rural communities experiencing the highest rates compared to urban areas. This concerning trend is particularly pronounced in West Virginia, which holds the record for the highest per-capita overdose rate in the nation, a state where more than 50% of the population resides in rural regions. Opioid use disorder (OUD) is closely associated with significantly increased morbidity and mortality, highlighting the severity of the public health crisis. Several factors contribute to this alarming rise, including increased access to opioids, socioeconomic challenges, and the ongoing prevalence of synthetic opioids like fentanyl, which exacerbate the overdose crisis. The pervasive impact of opioid use disorder on public health, especially in rural settings, calls for urgent intervention and targeted strategies to reduce overdose fatalities and improve access to care and treatment for affected individuals [1].

Naloxone: A Critical Intervention in Opioid Overdose Management

Naloxone, a medication used for over 50 years to reverse opioid toxicity, has become a cornerstone in preventing opioid overdose fatalities. As a competitive antagonist at the μ-opioid receptor, naloxone effectively counteracts the life-threatening effects of opioid overdose, particularly respiratory depression. Traditionally available as a parenteral formulation, naloxone has become more widely accessible, with the federal government recommending its over-the-counter availability in pharmacies to enhance its accessibility to the general public. As of now, naloxone can be acquired without a prescription in 43 states, making it more accessible to emergency medical responders, law enforcement officers, and individuals who may need to administer it in a crisis situation. This expanded availability ensures that family members and caregivers of individuals with opioid use disorder can readily access and administer naloxone, potentially saving lives during opioid overdose emergencies [1]. The increased availability of naloxone represents a pivotal strategy in combating the opioid crisis and addressing the public health challenges posed by opioid-related deaths.

FDA-Approved Indications for Naloxone

Naloxone is primarily indicated for the treatment of opioid toxicity, specifically to reverse respiratory depression caused by opioid use. This medication proves invaluable in both accidental and intentional overdoses, as well as in cases of acute and chronic opioid toxicity. Naloxone has been used successfully in managing overdoses from a range of substances, including heroin, fentanyl, carfentanil, hydrocodone, oxycodone, and methadone. A notable alert from the Centers for Disease Control and Prevention (CDC) in October 2015 highlighted a sharp increase in fentanyl-related accidental overdose deaths, which were attributed to illicitly manufactured fentanyl. The CDC updated its warning in August 2016 in response to the growing prevalence of counterfeit opioid pills circulating on the black market, which often contain fentanyl and other similar potent compounds in varying concentrations. This underscores the critical need for healthcare providers to remain vigilant regarding the potential for fentanyl contamination in street drugs. In a February 2017 case report featured in the CDC's Morbidity and Mortality Weekly Report (MMWR), multiple opioid overdoses were documented in patients who, unaware of their exposure, believed they were using cocaine, only to discover that the substance was fentanyl mixed with trace amounts of cocaine. This highlights the importance of considering opioid co-ingestion in patients who present with overdose symptoms, particularly in cases involving multiple illicit substances [2][3]. According to the American Heart Association (AHA), most opioid overdoses progress to out-of-hospital cardiac arrest due to airway obstruction and respiratory failure, reinforcing the need for immediate naloxone administration coupled with interventions to maintain airway patency and stabilize the patient [4].

Off-Label Uses

The naloxone challenge test serves as a diagnostic tool used to assess and quantify the physiological level of opioid dependence by administering naloxone, an opioid receptor antagonist. This test is utilized to evaluate the absence of physical opioid dependence, and it is typically administered to patients who have reported an adequate period of opioid abstinence and have tested negative for opioids through urine analysis. Naloxone can be administered intravenously, subcutaneously, or intramuscularly. However, a negative result from the naloxone challenge does not necessarily guarantee that the patient will not experience opioid withdrawal symptoms upon the administration of naltrexone. This test plays an essential role in the management of opioid use disorder (OUD) [5]. Furthermore, the American Society of Clinical Oncology (ASCO) guidelines recommend the use of low-dose naloxone infusion in combination with other therapeutic strategies for the management of pruritus in cancer patients [6]. Additionally, evidence suggests that naloxone may be beneficial in the treatment of chronic kidney disease-associated pruritus (CKD-aP), although further research is necessary to confirm these findings [7][8][9].

Mechanism of Action

Naloxone acts as a pure, competitive opioid antagonist, exhibiting the highest affinity for the μ-opioid receptor, which allows it to reverse the effects of opioids. Research indicates that naloxone exerts its antagonistic effects by binding competitively to the μ, κ, and σ-opioid receptors within the central nervous system (CNS), with the highest affinity for the μ receptor. At lower dosages, naloxone primarily blocks the μ-opioid receptors, while having a minimal effect on the δ and κ receptors. This selective receptor activity contributes to its efficacy in reversing opioid-induced respiratory depression and other opioid-related effects at therapeutic doses [10].

Pharmacokinetics

Absorption: The onset of naloxone's action is rapid, with effects observable within one minute when administered intravenously (IV) or intraosseously (IO). When delivered via nasal spray, naloxone exhibits a bioavailability of approximately 50%. In most cases of opioid overdose, the reversal of symptoms is noticeable within minutes of administration. If no signs of reversal are observed after the administration of 10 mg of naloxone, clinicians should consider the possibility of co-ingestants, such as alcohol, benzodiazepines, cocaine, or methamphetamine, that may complicate the overdose [11][12]. Overdoses involving fentanyl often necessitate higher doses of naloxone for effective reversal [13].

Distribution: Naloxone is widely distributed throughout the body and is able to cross the placenta. It binds weakly to plasma proteins, primarily albumin.

Metabolism: Naloxone is metabolized in the liver via glucuronide conjugation [14].

Excretion: Between 25% and 40% of naloxone is eliminated as metabolites in the urine within six hours post-administration, with up to 70% excreted within 72 hours. Following intranasal administration, the plasma half-life of naloxone hydrochloride ranges from 1.85 to 2.08 hours in healthy adults, which is longer than the half-life observed after intramuscular injection (1.24 hours).

Administration
Available Dosage Forms and Strengths

Naloxone is predominantly administered through intravenous (IV) routes, as this allows for rapid reversal of opioid effects. In cases where IV access is not possible, naloxone can be administered by alternative methods including intraosseous (IO), subcutaneous (SQ), intramuscular (IM), or intranasal (NAS) routes. When delivered intravenously, naloxone typically reverses opioid effects within minutes. The injectable formulation of naloxone is available in concentrations of 0.4 mg/mL and 1 mg/mL, as well as in a high-dose prefilled syringe containing 5 mg/0.5 mL. The intranasal formulation is offered in concentrations of 3 mg/0.1 mL, 4 mg/0.1 mL, and 8 mg/0.1 mL per actuation.

Adult Dosage

The dosage of naloxone should be titrated to enhance the patient's respiratory drive, facilitating adequate spontaneous respiration and oxygenation without fully reversing opioid effects. Full reversal can induce opioid withdrawal symptoms, which may manifest combative or aggressive behavior. For patients who are opioid-dependent, a modest initial IV dose (ranging from 0.04 mg to 0.1 mg) is recommended to avoid precipitating withdrawal. For individuals with no known opioid dependence, a larger initial dose of 0.4 mg is advised. In cases where patients exhibit apnea or near-apnea with cyanosis, particularly in the prehospital setting, providers are encouraged to administer larger initial doses, such as 1 mg to 2 mg IV or 2 mg via intranasal, IM, or SQ routes. Subsequent doses can be adjusted to range from 0.1 mg to 0.4 mg IV or 0.4 mg to 1 mg intranasally, IM, or SQ, with dosing repeated until the desired effect is achieved [15][16].

Continuous Intravenous Infusion (Off-Label)

For patients who overdose on long-acting opioids such as methadone, a continuous IV infusion of naloxone may prove beneficial. Clinicians may initiate this infusion by administering two-thirds of the initial effective naloxone dose (ranging from 0.1 to 6 mg/h) as a bolus every 60 minutes, or by delivering half of the initial bolus dose 15 minutes after starting the continuous infusion. This strategy ensures a sustained naloxone dose, which is crucial for counteracting the prolonged effects of long-acting opioids.

Endotracheal Administration (Off-Label)

Although naloxone is sometimes administered via an endotracheal tube by emergency medical personnel, there is limited evidence supporting the efficacy of this method. However, in critical emergency situations where other administration routes are unavailable, endotracheal administration may be deemed necessary. Typical naloxone doses for endotracheal administration range from 0.8 mg to 5 mg, depending on the clinical scenario.

Intranasal Spray

The U.S. Food and Drug Administration (FDA) recently approved an intranasal spray (NAS) for the administration of naloxone, available in the form of an autoinjector. This device delivers a 4 mg dose of naloxone, which can be utilized by caregivers or family members in emergency situations. The initial dose from the intranasal spray provides a 4 mg dose of naloxone, and the device is specifically recommended for use in non-healthcare settings. When using this agent to reverse an opioid overdose, several key recommendations are outlined: First, after administering the initial NAS dose, caregivers must immediately seek emergency medical assistance and should not assume the patient is fully recovered, even if mental function appears to return. The patient should be closely monitored for vital sign stability, and if signs of relapse occur, including a decrease in respiratory rate, a second dose may be required before emergency personnel arrive. If repeat dosing is necessary, the naloxone should be administered in alternating nostrils at intervals of 2 to 3 minutes. In cases where the patient does not respond to repeated doses, caregivers should be ready to perform additional resuscitative measures, such as cardiopulmonary resuscitation (CPR). A significant advantage of the NAS formulation is the elimination of needle-related risks, such as accidental needle sticks or contamination. Moreover, the NAS formulation does not require needles or the disposal of sharps. This innovation was developed to allow non-medically trained individuals to safely administer naloxone, particularly when opioid-induced respiratory depression is present. Unlike the parenteral route, the NAS avoids complications related to vein accessibility and needle disposal. However, despite the widespread promotion of NAS naloxone campaigns, the high cost of this formulation remains a barrier to broader acceptance, which may hinder the effectiveness of opioid overdose interventions unless a more affordable alternative becomes available.

Out-of-Hospital Use

Naloxone administration has proven effective in reversing opioid-induced respiratory depression and preventing out-of-hospital cardiac arrest (OA-OHCA). The presence of miosis (pupillary constriction) in a patient with altered mental status is a strong indication that naloxone will be effective in reversing the

overdose [4]. The American Heart Association (AHA) recommends that laypersons and individuals unable to reliably assess pulse presence should initiate cardiopulmonary resuscitation (CPR) in any unconscious, non-breathing individual. Additionally, the AHA advises administering naloxone if an opioid overdose is suspected [4].

Dosage Modifications (Partial Opioid Agonists or Mixed Agonists/Antagonists)

When a patient has overdosed on long-acting opioids or partial agonists, such as buprenorphine or pentazocine, the response to naloxone may be incomplete, and higher or repeated doses of naloxone may be necessary. In these cases, naloxone can be administered every 2 to 5 minutes as needed. For some patients, an intravenous naloxone infusion may be beneficial, ensuring a steady administration of naloxone to counteract the effects of the opioid overdose.

Dosing Considerations in the Emergency Department

Naloxone is not a replacement for emergency medical care, and clinicians must adhere to established trauma and Advanced Cardiovascular Life Support (ACLS) protocols when resuscitating patients. It is essential for healthcare providers to be aware that additional doses of naloxone may be required after the initial administration. Overdoses involving synthetic opioids, such as fentanyl or carfentanil, have become more prevalent, and in these cases, higher doses of naloxone, potentially exceeding 10 mg, may be needed. For instance, a study conducted at Jackson Memorial Hospital in Miami, Florida, reported a dramatic increase in opioid overdoses, with a 119% rise in overdose cases over a three-month period in 2016 compared to the same period in the previous year. The study also found a 476% increase in naloxone usage, which was attributed to the circulation of more potent synthetic opioids, such as fentanyl, in the heroin supply, compared to traditional heroin in 2015 [17]. For patients in the emergency department who require multiple doses of naloxone and are being considered for admission, a continuous naloxone infusion may be necessary. The typical infusion dose is approximately two-thirds of the patient's initial wake-up dose per hour, ensuring a steady naloxone presence in the system to reverse the effects of the opioid overdose effectively.

Failure to Respond to Naloxone Doses

In instances where a patient does not respond to repeated doses of naloxone, clinicians must consider alternative causes for the patient’s unconsciousness. Once the acute phase of the overdose has been managed, it is imperative for the patient to be referred to substance use disorder treatment services and encouraged to participate in rehabilitation programs to address the underlying addiction issues [18][19]. The 2022 guidelines from the Centers for Disease Control and Prevention (CDC) offer crucial recommendations for clinicians prescribing opioids. Specifically, they advise against escalating opioid doses to 50 morphine milligram equivalents (MME) per day or higher without caution. Research indicates that doses above this threshold are unlikely to substantially improve pain relief for most patients, while simultaneously heightening the risk of overdose. Therefore, when a patient's total opioid dosage from all sources reaches or exceeds 50 MME/day, healthcare providers must implement additional safeguards. These include scheduling more frequent follow-up visits and educating not only the patient but also their household members about naloxone use and overdose prevention strategies [20].

Specific Patient Populations

Several patient populations may require specialized considerations when administering naloxone. Patients with hepatic impairment, including those with chronic liver diseases such as alcoholic liver disease or viral hepatitis (B or C), often present in opioid overdose cases. However, naloxone does not appear to worsen these liver conditions [14]. In individuals with renal impairment, naloxone has been shown to improve symptoms of chronic kidney disease-associated pruritus (CKD-aP), though it is recommended to use a cautious, low-dose approach in these patients [7]. For pregnant women, the American Society of Addiction Medicine (ASAM) guidelines recommend naloxone administration during opioid overdose events, as it is considered safe for use in this population. Furthermore, naloxone may be utilized alongside buprenorphine/naloxone formulations for managing opioid use disorder in pregnancy, as the naloxone

component has minimal systemic absorption when taken as prescribed. However, naloxone should not be used as a diagnostic tool to assess opioid dependence in pregnant women, as this may precipitate withdrawal, which can lead to complications such as preterm labor or fetal distress [21]. Regarding breastfeeding, naloxone is minimally excreted into breast milk, and due to its low oral bioavailability, it is not detectable in the plasma of infants who are breastfed. Naloxone has no effect on oxytocin or prolactin levels, making it safe for use in breastfeeding mothers [22].

Pediatric and Older Patients

Among pediatric patients, particularly adolescents, opioid overdose remains a significant concern. The mortality rate due to unintentional overdose among adolescents surged in 2020, with fentanyl and other synthetic opioids responsible for 81% of these deaths. The effectiveness of interventions such as Medications for Opioid Use Disorder (MOUD) and harm-reduction strategies, including naloxone, has been well-documented and continues to be crucial in addressing this public health issue [23]. Older adults also face heightened risks associated with opioid use, particularly due to declines in renal, hepatic, and cardiac function, as well as polypharmacy. These factors can result in increased systemic exposure to naloxone, which requires careful monitoring. The National Poison Data System has reported an increased prevalence of severe medical outcomes related to opioid exposure in older adults, underscoring the need for vigilant care in this population [24].

Adverse Effects

The primary adverse effects linked to naloxone are typically observed following acute opioid withdrawal. These effects include anxiety, aggression, nausea, vomiting, diarrhea, abdominal discomfort, and rhinorrhea. In rare instances, naloxone administration has been associated with the onset of noncardiogenic pulmonary edema. The estimated incidence of naloxone-induced noncardiogenic pulmonary edema ranges from 0.2% to 3.6% in patients who are transported to the emergency department after receiving naloxone. This condition is characterized by persistent hypoxia, which persists despite the resolution of respiratory depression induced by the opioid overdose. Patients may present with a productive cough, often yielding the distinctive "pink, frothy sputum" commonly associated with pulmonary edema. Chest radiographs in these cases typically reveal the expected findings of pulmonary edema. Onset of this condition generally occurs within 4 hours following naloxone administration, though delayed onset has been reported up to 8 hours post-administration [16][25]. Naloxone is also included in the Key Potentially Inappropriate Drugs in Pediatrics (KIDs List), primarily due to the heightened risk of seizures, necessitating extreme caution when administered to neonates for postpartum resuscitation [26].

Contraindications

There are no absolute contraindications to the use of naloxone in emergency settings. The only relative contraindication is a known hypersensitivity to naloxone itself.

Warnings and Precautions

The Centers for Disease Control and Prevention (CDC) guidelines acknowledge the potential for severe adverse reactions, such as pulmonary edema, cardiovascular instability, and seizures, although these occurrences are rare when naloxone is administered according to recommended dosages for opioid overdose management [20]. According to the American Society of Addiction Medicine (ASAM), the onset of maximal precipitated withdrawal varies depending on the mode of naloxone administration. For intravenous (IV) naloxone, withdrawal symptoms typically peak within 1 minute, whereas after intramuscular (IM) naloxone, the onset is usually several minutes. Extended-release injectable naltrexone may induce withdrawal effects hours after administration [21].

Monitoring

Patients who experience opioid overdose are at heightened risk for respiratory depression and hypotension and should be resuscitated and monitored accordingly. Naloxone administration itself may precipitate an acute withdrawal syndrome, presenting symptoms such as nausea, diaphoresis, vomiting,

tachycardia, and even cardiac arrest. In individuals with chronic opioid use, naloxone should be administered gradually to avoid exacerbating withdrawal symptoms. Patients who have responded to naloxone must be continuously monitored for 6 to 12 hours due to the longer half-lives of certain opioids, such as methadone, fentanyl, and buprenorphine, which can outlast the effects of naloxone. The half-life of naloxone in adults ranges from 30 to 80 minutes. Vital signs, including pulse oximetry, should be monitored until full recovery is achieved. Even after the reversal of respiratory depression, it is crucial to maintain observation for 6 to 12 hours since longer-acting opioids may continue to exert their effects after naloxone has been cleared from the system. Any patient requiring more than 5 mg of IV naloxone should be admitted for further monitoring. For patients whose respiratory depression is fully reversed with naloxone doses of 0.4 to 2 mg, it is recommended that they be observed in the emergency room for 2 to 4 hours. If the patient remains stable, discharge is advised. Discharge is typically considered for patients who meet the following criteria: a Glasgow coma scale of 15, no further need for naloxone doses, oxygen saturation of at least 92% on room air, respiration rate no less than 10 breaths per minute, pulse rate between 50 and 120 beats per minute, blood pressure between 110/90 and 140/90 mm Hg, the ability to tolerate clear liquids, ambulate, and absence of withdrawal symptoms. Furthermore, it is essential that patients have someone available to drive them home and monitor their condition for the subsequent 12 to 24 hours [27].

Current Guidelines

In response to the ongoing opioid crisis, recent legislation in the United States has facilitated the prescription of naloxone by physicians to patients diagnosed with opioid use disorder, as a measure to reverse opioid overdose. Additionally, more than a dozen states have enacted Good Samaritan laws, which empower healthcare professionals to prescribe naloxone to the family members or caregivers of patients affected by opioid use disorder. This legislative shift is part of broader national campaigns aimed at improving the accessibility of naloxone, targeting a wide array of professionals such as firefighters, law enforcement officers, and other first responders [28][29]. These efforts are designed to combat the rising overdose death toll by ensuring that naloxone, a life-saving intervention, is readily available to those in need.

Naloxone Storage

Naloxone should be stored at room temperature, within a protective outer case designed to make it impact-resistant and easily transportable, particularly in emergency medical settings such as ambulances. The Substance Abuse and Mental Health Services Administration (SAMHSA) advocates for the prescription of automatic injection devices or nasal sprays containing naloxone, ensuring the drug’s immediate availability for patients at risk of overdose. Healthcare providers must remain vigilant about the need to replace naloxone upon its expiration and in cases where it has been exposed to temperature extremes—below 3.8 °C (39 °F) or above 40 °C (104 °F). Proper storage is essential to maintain the efficacy of naloxone, enabling healthcare professionals to provide timely intervention when necessary.

Discussion

Addressing concerns regarding naloxone administration can be effectively achieved through appropriate training for healthcare professionals. Patients must also be educated about the potential risks after naloxone administration, specifically the possibility of respiratory depression once the drug's pharmacological effects dissipate. This education is critical to ensuring that patients and caregivers understand the necessity of ongoing monitoring and the potential for relapsing into respiratory compromise after initial reversal of overdose symptoms.

Prescription Drug Monitoring Program (PDMP)

A Prescription Drug Monitoring Program (PDMP) is an electronic tool used to track prescriptions for controlled substances. PDMPs are invaluable in identifying patients who may be at risk for opioid overdose by providing insight into a patient’s prescription history, especially in cases where medication history is unavailable or during transitions between healthcare providers. The use of PDMPs is a vital component of improving opioid prescribing practices. Healthcare providers are encouraged to regularly

review PDMP data to evaluate opioid prescriptions and the use of other controlled medications, including combinations that may elevate the risk of overdose, such as opioids in conjunction with benzodiazepines. According to CDC guidelines, PDMP usage should be mandatory when initiating opioid therapy for acute, subacute, or chronic pain and should occur at least every three months, or more frequently, if the opioid regimen is ongoing. This approach aims to mitigate the risks associated with long-term opioid use and reduce the likelihood of overdose incidents.

Toxicity

The rapid reversal of narcotic-induced depression following naloxone administration can lead to adverse cardiovascular outcomes, such as tachycardia, hypertension, and, in extreme cases, cardiac arrest, particularly in hypoxic states typical of opioid overdose. The concomitant use of substances like cocaine can amplify these risks. Additionally, there have been documented instances of pulmonary edema following naloxone administration. Although the exact mechanisms remain unclear, it is hypothesized that a centrally mediated increase in catecholamine levels may lead to a significant shift in blood volume into the pulmonary vascular bed, thereby raising hydrostatic pressures. A study involving 36 patients with acute ischemic cerebral infarction administered high doses of naloxone to assess its efficacy and toxicity. Each participant received an initial loading dose of 160 mg/m2, followed by a continuous infusion of 80 mg/m2/h for 24 hours. While there were no statistically significant changes in group mean arterial pressure, respiratory rate, or heart rate in response to the loading dose or infusion, clinically significant changes were observed in four patients. Adverse reactions potentially linked to naloxone were reported in 23 patients, with nausea being the most frequent, followed by bradycardia, myoclonus, and hypertension. Naloxone was discontinued in seven cases due to potential adverse effects, all of which were resolved after discontinuation and appropriate pharmacological management. No fatalities were attributed to naloxone treatment [30][31].

Management of Overdose

Patients who experience naloxone overdose should be managed with symptomatic treatment under careful medical supervision. Physicians are encouraged to contact a poison control center for the most current information on managing overdose situations. This ensures that appropriate therapeutic interventions are utilized to mitigate adverse effects.

Enhancing Healthcare Team Outcomes

Over the past two decades, numerous community-based educational campaigns have been launched to raise awareness about opioid use and overdose prevention. These community outreach programs are credited with preventing more than 10,000 opioid overdoses. A more recent pilot study highlights that individuals who received overdose education, coupled with naloxone rescue kits, did not exhibit differences in overdose rates, opioid use, or responses to witnessed overdoses compared to those who only received overdose education, demonstrating the importance of training in opioid overdose prevention. Despite the success of these educational initiatives, the majority of these campaigns have been concentrated in urban areas. To create a significant impact, similar outreach programs must be extended to rural communities, where the highest rates of opioid overdoses are observed. While the idea of making naloxone available as an over-the-counter medication is a valuable and practical concept, concerns regarding proper administration persist. With adequate resources and support, individuals seeking to self-administer naloxone can overcome barriers to understanding the instructions. Empowering individuals to take control of their health and well-being is essential for the success of these initiatives. A further challenge lies in the rapid onset of moderate-to-severe withdrawal symptoms following naloxone administration, which, in many instances, can be intense and may require immediate medical attention. Currently, pharmacists and nurses play a vital role in educating the public about opioid overdose risks and their management. Nurses have been actively providing education in schools, colleges, and workplaces, highlighting the signs and symptoms of opioid overdose and the appropriate indications for naloxone administration. Pharmacists are also educating individuals who receive narcotic prescriptions about the

benefits of keeping naloxone at home as part of their safety plan [32][33]. Additionally, patients should be informed that alternative methods of pain management are not only safer but also as effective as opioids.

Outcomes

Naloxone has been a cornerstone in opioid overdose management in the United States for over 50 years, during which it has reversed more than 10,000 opioid-related overdoses. Despite its proven efficacy and safety, the use of naloxone remains controversial in some states, and concerns about withdrawal reactions persist. Nevertheless, naloxone is steadily gaining broader acceptance within American society, further supported by the passage of Good Samaritan laws, which have facilitated its availability as an over-the-counter drug. Naloxone's ability to reverse opioid overdoses is undisputed, yet consultation with addiction medicine specialists and psychiatrists is recommended for individuals with opioid use disorder to ensure the optimal use of naloxone and to improve patient outcomes [34][35].

Conclusion:

The opioid overdose crisis in the United States has reached alarming levels, with rural areas bearing the brunt of the epidemic. Naloxone, a competitive opioid receptor antagonist, has emerged as a vital intervention to counteract the potentially fatal effects of opioid overdose, particularly respiratory depression. This medication has been an essential tool in reversing opioid-induced fatalities, especially given the prevalence of synthetic opioids like fentanyl, which have intensified the crisis. The widespread availability of naloxone, including in pharmacies without prescriptions in 43 states, has facilitated its use in both clinical and non-clinical settings. Its use by emergency responders, law enforcement officers, and even family members has proven effective in saving lives during opioid overdose emergencies. Naloxone is FDA-approved for the treatment of opioid toxicity and has been demonstrated to reverse overdoses from various opioids, including heroin, fentanyl, and prescription painkillers. Its rapid onset of action, particularly when administered intravenously or intranasally, is crucial in emergency situations. The growing use of naloxone in prehospital settings reflects its effectiveness in saving lives and reducing the incidence of opioid-related deaths. However, its use is not without challenges.

Overdoses involving potent opioids like fentanyl may require higher doses or multiple administrations of naloxone, highlighting the need for healthcare providers to remain vigilant. Beyond its traditional use for overdose reversal, naloxone has been investigated for off-label applications, such as its role in opioid use disorder treatment and cancer-related pruritus. Despite these promising findings, more research is needed to fully understand the broader potential of naloxone in clinical practice. The availability of naloxone in various dosage forms, including intranasal sprays, has made it more accessible, eliminating the risks associated with needle use. Nevertheless, the high cost of certain naloxone formulations remains a significant barrier to widespread access, particularly in underserved communities. In conclusion, naloxone has proven to be an indispensable part of efforts to combat the opioid crisis. As opioid overdoses continue to rise, expanding access to naloxone remains a critical strategy for saving lives and addressing the public health challenges posed by the epidemic. Enhanced training for laypersons and increased funding for naloxone distribution programs are essential steps to further mitigate opioid overdose fatalities.

References:

[1] Qayyum SN, Ansari RS, Ullah I, Siblini D. The FDA approves the second OTC naloxone - a step toward opioid crisis mitigation. Int J Surg. 2023 Dec 01;109(12):4349-4350.

[2] Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A, Wang Y, Halpin J, Zibbell J, McCarty CL, DeFiore-Hyrmer J, DiOrio M, Goldberger BA. Increases in Fentanyl-Related Overdose Deaths - Florida and Ohio, 2013-2015. MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):844-9.

[3] Tomassoni AJ, Hawk KF, Jubanyik K, Nogee DP, Durant T, Lynch KL, Patel R, Dinh D, Ulrich A, D'Onofrio G. Multiple Fentanyl Overdoses - New Haven, Connecticut, June 23, 2016. MMWR Morb Mortal Wkly Rep. 2017 Feb 03;66(4):107-111.

[4] Dezfulian C, Orkin AM, Maron BA, Elmer J, Girotra S, Gladwin MT, Merchant RM, Panchal AR, Perman SM, Starks MA, van Diepen S, Lavonas EJ., American Heart Association Council on Cardiopulmonary,

Critical Care, Perioperative and Resuscitation; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Council on Clinical Cardiology. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. Circulation. 2021 Apr 20;143(16):e836-e870.

[5] Jones JD, Sherwin E, Martinez S, Comer SD. Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples. Am J Addict. 2020 Jan;29(1):51-56.

[6] Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, Kong LR, Kurita GP, LeBlanc TW, Mercadante S, Novick KLM, Sedhom R, Seigel C, Stimmel J, Bruera E. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023 Feb 01;41(4):914-930.

[7] Pereira MP, Zeidler C, Ständer S. Improvement of Chronic Kidney Disease-Associated Pruritus After Treatment With Intravenous Naloxone. JAMA Dermatol. 2021 Nov 01;157(11):1380-1381.

[8] Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015 Apr;87(4):685-91.

[9] Boehlke C, Joos L, Coune B, Becker C, Meerpohl JJ, Buroh S, Hercz D, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev. 2023 Apr 14;4(2023):CD008320.

[10] Trøstheim M, Eikemo M, Haaker J, Frost JJ, Leknes S. Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade. Neuropsychopharmacology. 2023 Jan;48(2):299-307.

[11] Zschoche JH, Nesbit S, Murtaza U, Sowell A, Waldfogel JM, Arwood N, Rush J, McNamara L, Swarthout M, Nesbit T, Ortmann M. Development and implementation of procedures for outpatient naloxone prescribing at a large academic medical center. Am J Health Syst Pharm. 2018 Nov 15;75(22):1812-1820.

[12] Leece P, Orkin A, Shahin R, Steele LS. Can naloxone prescription and overdose training for opioid users work in family practice? Perspectives of family physicians. Can Fam Physician. 2015 Jun;61(6):538-543.

[13] Barr, C. A., Haughan, J., Gianotti, G., Varner, K., Drobatz, K. J., Stefanovski, D., ... & Otto, C. M. (2023). Pharmacokinetics and pharmacodynamics of intranasal and intramuscular administration of naloxone in working dogs administered fentanyl. *Journal of Veterinary Internal Medicine*, *37*(6), 2422-2428.

[14] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Mar 24, 2020. Naloxone.

[15] Peglow SL, Binswanger IA. Preventing Opioid Overdose in the Clinic and Hospital: Analgesia and Opioid Antagonists. Med Clin North Am. 2018 Jul;102(4):621-634.

[16] Hedberg K, Bui LT, Livingston C, Shields LM, Van Otterloo J. Integrating Public Health and Health Care Strategies to Address the Opioid Epidemic: The Oregon Health Authority's Opioid Initiative. J Public Health Manag Pract. 2019 May/Jun;25(3):214-220.

[17] Bode AD, Singh M, Andrews J, Kapur GB, Baez AA. Fentanyl laced heroin and its contribution to a spike in heroin overdose in Miami-Dade County. Am J Emerg Med. 2017 Sep;35(9):1364-1365.

[18] Chouinard S, Prasad A, Brown R. Survey Assessing Medical Student and Physician Knowledge and Attitudes Regarding the Opioid Crisis. WMJ. 2018 Mar;117(1):34-37.

[19] Blandthorn J, Bowman E, Leung L, Bonomo Y, Dietze P. Managing opioid overdose in pregnancy with take-home naloxone. Aust N Z J Obstet Gynaecol. 2018 Aug;58(4):460-462.

[20] Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 04;71(3):1-95.

[21] The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91.

[22] Myklebust, T., La Rooy, D. J., & Peixtoto, C. E. (2023). The National Institute of Child Health and Human Development Protocol. *Interviewing and interrogation: a review of research and practice since World War II*, 367-387.

[23] Hermans SP, Samiec J, Golec A, Trimble C, Teater J, Hall OT. Years of Life Lost to Unintentional Drug Overdose Rapidly Rising in the Adolescent Population, 2016-2020. J Adolesc Health. 2023 Mar;72(3):397-403.
[24] Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham NPT, Bronstein AC, DesLauriers C. 2022 Annual Report of the National Poison Data System® (NPDS) from America's Poison Centers®: 40th Annual Report. Clin Toxicol (Phila). 2023 Oct;61(10):717-939.
[25] Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol. 2018 Jan 06;58:143-159.
[26] Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, Hoff DS. *K*ey Potentially *I*nappropriate *D*rugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191.
[27] Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol (Phila). 2017 Feb;55(2):81-87.
[28] Hamel MG. Revisiting Naloxone: A different take on overdose guidelines from Lee County, Fla. JEMS. 2016 Nov;41(11):46-8.
[29] Soelberg CD, Brown RE, Du Vivier D, Meyer JE, Ramachandran BK. The US Opioid Crisis: Current Federal and State Legal Issues. Anesth Analg. 2017 Nov;125(5):1675-1681.
[30] Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015 Feb;6(1):20-31.
[31] Barsan WG, Olinger CP, Adams HP, Brott TG, Eberle R, Biller J, Biros M, Marler J. Use of high dose naloxone in acute stroke: possible side-effects. Crit Care Med. 1989 Aug;17(8):762-7
[32] Gilmartin-Thomas JF, Bell JS, Liew D, Arnold CA, Buchbinder R, Chapman C, Cicuttini F, Dobbin M, Gibson SJ, Giummarra MJ, Gowan J, Katz B, Lubman DI, McCrone M, Pilgrim J, Synnot A, van Dyk E, Workman B, McNeil J. Chronic pain medication management of older populations: Key points from a national conference and innovative opportunities for pharmacy practice. Res Social Adm Pharm. 2019 Feb;15(2):207-213.
[33] Duvivier H, Gustafson S, Greutman M, Jangchup T, Harden AK, Reinhard A, Warshany K. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone. J Am Pharm Assoc (2003). 2017 Mar-Apr;57(2S):S135-S140.
[34] Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011 - 2017. Drug Alcohol Depend. 2018 Oct 01;191:361-364.
[35] Madah-Amiri D, Gjersing L, Clausen T. Naloxone distribution and possession following a large-scale naloxone programme. Addiction. 2019 Jan;114(1):92-100.

نالوكسون - نظرة عامة على ترياق الأفيونات

الملخص:

الخلفية: ارتفعت معدلات الجرعات الزائدة من الأفيونات في الولايات المتحدة، وخاصة في المناطق الريفية، حيث زاد اضطراب استخدام الأفيونات (OUD) بشكل كبير من المرض والوفاة. تُغذّي أزمة الأفيونات عدة عوامل، بما في ذلك انتشار الأفيونات الاصطناعية مثل الفنتانيل. أصبح النالوكسون، وهو دواء يُستخدم لأكثر من خمسة عقود، أداة حيوية في عكس سمّية الأفيونات، خاصة في الحالات الطارئة.

الهدف: يهدف هذا الاستعراض إلى تقديم نظرة عامة على النالوكسون، علم العقاقير الخاص به، آليات عمله، التطبيقات السريرية، ودوره الحيوي في تقليل وفيات الجرعات الزائدة من الأفيونات.

الطرق: يستعرض هذا المقال المعرفة الحالية عن النالوكسون، مع التركيز على دلالاته، فعاليته، طرق إعطائه، وأشكاله الجرعية المتاحة. تم استخلاص البيانات من الإرشادات الطبية، الدراسات البحثية، وتقارير مراكز السيطرة على الأمراض (CDC).

النتائج: أظهر النالوكسون فعالية كبيرة في عكس تأثيرات الجرعات الزائدة من الأفيونات، وخاصة تثبيط التنفس. أصبح الآن متاحًا على نطاق واسع، بما في ذلك كخيار بدون وصفة طبية في 43 ولاية. توفر طرق الإعطاء المختلفة مثل الحقن الوريدي، والعن طريق الأنف، والعضلي مرونة للاستخدام في البيئات السريرية وما قبل المستشفى. أظهرت الاستخدامات غير المدرجة للنالوكسون، مثل إدارة اضطراب استخدام الأفيونات والحكة في مرضى السرطان، نتائج واعدة، على الرغم من الحاجة إلى مزيد من البحث.

الخاتمة: يظل النالوكسون مكونًا أساسيًا في استجابة الصحة العامة لأزمة الأفيونات. لقد مكن توفره الواسع وطرق إعطائه المتنوعة من التدخل في الوقت المناسب في حالات الجرعات الزائدة من الأفيونات، مما أنقذ العديد من الأرواح. هناك حاجة إلى زيادة الوعي والوصول إلى النالوكسون للحد من وفيات الجرعات الزائدة من الأفيونات، خاصة في المجتمعات الريفية التي تأثرت بشكل كبير بالأزمة.

الكلمات المفتاحية: نالوكسون، جرعة زائدة من الأفيونات، اضطراب استخدام الأفيونات، سمّية الأفيونات، عكس الجرعة الزائدة، تثبيط التنفس، الصحة العامة، الفنتانيل.